Monsanto Company
By Terry McDonald on May 24, 2011
Tags: Ambergate Trust, Artal Luxembourg S.A., Ceres Inc., Hambrecht Quist Management Inc., KBC Group, Monsanto Company, Oppenheimer Growth Fund, Questmark Partners, Soros Private Equity Partners, Warburg Pincus Private Equity IX L.P., Brazil, United States, USD, Artal Luxembourg, Ceres, Warburg Pincus, biofuels, biofuels, biotechnology, biotechnology, California, chemicals, energy, Finance, IPO, venture capital
Agricultural biotechnology company Ceres, Inc., based in Thousand Oaks, California, filed an Initial Public Offering prospectus with the U.S. regulators Monday planning to raise up to $100 million and to list on NASDAQ under the symbol CERE.
By Terry McDonald on July 21, 2010
Tags: Archer Daniels Midland Company, BP plc, Conocophillips, Cosan Ltd., Deere Co., Dupont, DuPont Danisco Cellulosic Ethanol LLC, EBoom Capital, ExxonMobil Corporation, Iogen Energy, Lawrence Berkeley National Laboratory, Logen Energy, Martek Biosciences Corporation, Monsanto, Monsanto Company, POET LLC, Pont de Nemours Company, Royal Dutch Shell PLC, Synthetic Genomics Inc, Tropical BioEnergia SA, Valero Energy Corp., Verenium Corp., Virent Energy Systems Inc., Brazil, United States, SGD, USD, algae oil, biobutanol, biodiesel, biofuel feedstock, BP, cellulosic ethanol, NASDAQ:VRNM, NYSE: ADM, NYSE: COP, NYSE: CZZ Cosan Limited, NYSE: DD, NYSE: DE, NYSE: MON, NYSE: RDS:A, NYSE: VLO, NYSE:BP, NYSE:XOM, Q1 2010 profits, biofuels, biotechnology, California, chemical, Colorado, energy, food, Hawaii, Illinois, Massachusetts, oil, Oregon, Tennessee, Texas, University of California, University of Illinois, Urbana Champaign, Wisconsin
While the ethanol subsidy debate rages in Washington, D.C., the big oil and chemical companies continue their small experiments into next-generation biofuels.
By Robert Gluck on June 17, 2010
Tags: Akzo Nobel, Monsanto Company, Monsanto Venture Capital, OPX Biotechnology Inc., Specialty Polymers Group, USD, biochemicals, biotechnology, Charles Eggert, Dr. Michael Lynch, Dr. Ryan Gill, EDGE, efficiency directed genome engineeering, OPX Biotechnology Inc., OPXBIO, biofuels, biotechnology, biotechnology, Charles Eggert, chemical, Colorado, finance, genetic engineering, Michael Lynch, Minnesota, Robert Gluck, Ryan Gill, University of Minnesota, Washington University in St. Louis
In this first part of my three part interview with OPX Biotechnology’s President and CEO Charles Eggert, he discusses his background, this history and mission of OPX and the company’s efficiency directed genome engineering (EDGE) technology.
ROBERT GLUCK: Please tell our readers a little bit about your background.
